After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

Multimodal treatment of resectable pancreatic ductal adenocarcinoma / Silvestris, Nicola; Brunetti, Oronzo; Vasile, Enrico; Cellini, Francesco; Cataldo, Ivana; Pusceddu, Valeria; Cattaneo, Monica; Partelli, Stefano; Scartozzi, Mario; Aprile, Giuseppe; Casadei Gardini, Andrea; Morganti, Alessio Giuseppe; Valentini, Vincenzo; Scarpa, Aldo; Falconi, Massimo; Calabrese, Angela; Lorusso, Vito; Reni, Michele; Cascinu, Stefano. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 111:(2017), pp. 152-165. [10.1016/j.critrevonc.2017.01.015]

Multimodal treatment of resectable pancreatic ductal adenocarcinoma

Scartozzi, Mario;Casadei Gardini, Andrea;Cascinu, Stefano
2017

Abstract

After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.
4-feb-2017
111
152
165
Multimodal treatment of resectable pancreatic ductal adenocarcinoma / Silvestris, Nicola; Brunetti, Oronzo; Vasile, Enrico; Cellini, Francesco; Cataldo, Ivana; Pusceddu, Valeria; Cattaneo, Monica; Partelli, Stefano; Scartozzi, Mario; Aprile, Giuseppe; Casadei Gardini, Andrea; Morganti, Alessio Giuseppe; Valentini, Vincenzo; Scarpa, Aldo; Falconi, Massimo; Calabrese, Angela; Lorusso, Vito; Reni, Michele; Cascinu, Stefano. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 111:(2017), pp. 152-165. [10.1016/j.critrevonc.2017.01.015]
Silvestris, Nicola; Brunetti, Oronzo; Vasile, Enrico; Cellini, Francesco; Cataldo, Ivana; Pusceddu, Valeria; Cattaneo, Monica; Partelli, Stefano; Scartozzi, Mario; Aprile, Giuseppe; Casadei Gardini, Andrea; Morganti, Alessio Giuseppe; Valentini, Vincenzo; Scarpa, Aldo; Falconi, Massimo; Calabrese, Angela; Lorusso, Vito; Reni, Michele; Cascinu, Stefano
File in questo prodotto:
File Dimensione Formato  
silvestris2017.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 840.85 kB
Formato Adobe PDF
840.85 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1177445
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact